Regency Centers Corp (REG) Stock News

Rosen Law Firm is reminding investors who purchased Datavault AI Inc. securities between September 4, 2024 and October 30, 2025 of an important October 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding corporate partnerships, overstated trading activity on the Datavault Platform, and failed to disclose connections with a convicted felon, causing reputational harm.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors who purchased Hertz Global Holdings (NASDAQ: HTZ) common stock between May 7, 2026 and June 23, 2026 of an important September 22, 2026 deadline to serve as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Hertz made materially false and misleading statements regarding its liquidity position, mischaracterizing market softness as transitory when it was actually recurring, and failing to disclose the need for a dilutive, distressed capital raise that would harm shareholders.

Rosen Law Firm reminds investors of the September 22, 2026 lead plaintiff deadline in a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created excess inventory of over 10,000 units, exposing the company to material operational and financial risks.

REGL is a smart beta ETF focused on mid-cap dividend aristocrats with $1.78 billion in assets. The fund has delivered 12.47% returns year-to-date and 10.97% over the past year, with a 2.17% dividend yield and 0.40% expense ratio. It carries medium risk with a beta of 0.71 and holds about 66 stocks across financials, industrials, and utilities sectors.

A securities class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group stock. The defendants, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during February 2025 to April 2026 that triggered a short squeeze, artificially inflating the stock price and benefiting their holdings. Investors who purchased Avis securities during this period may be eligible for compensation, with a September 29, 2026 deadline to serve as lead plaintiff.

Klépierre, Europe's leading shopping mall operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million. The company demonstrated strong execution in a dynamic retail market, driving organic growth. As of July 31, 2026, the company had 286.86 million shares outstanding.

The Schall Law Firm is seeking investors to join a class action lawsuit against Regeneron Pharmaceuticals for securities fraud. The company allegedly made false and misleading statements about its Phase III Fianlimab-Libtayo study, claiming it was likely to succeed when it actually failed to demonstrate clinical differentiation from competing therapies. Investors who purchased securities between August 1, 2025 and May 15, 2026 are encouraged to participate before the September 14, 2026 deadline.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made false statements about trial progress while concealing that preliminary statistical assumptions were flawed and the treatment showed no meaningful differentiation over standard therapies. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Erasca, Inc., which allegedly made false and misleading statements about its lead oncology drug candidate ERAS-0015, claiming it was 'best-in-class' while failing to disclose improper comparisons to competitors and lacking reasonable basis. The firm is seeking lead plaintiffs with an August 10, 2026 deadline for Erasca and August 4, 2026 for PicS N.V.

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026, with a lead plaintiff deadline of September 14, 2026.

Rosen Law Firm reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors who purchased stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when defendants knew of significant viability problems that would negatively impact the business.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance on May 15, 2026, resulting in an $11 billion market cap loss. The lawsuit covers investors who purchased shares between August 1, 2025 and May 15, 2026.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PicS N.V., alleging the company made false and misleading statements in its January 2026 IPO offering documents. The lawsuit claims PicS failed to disclose deficient credit evaluation procedures, material reclassifications of credit exposures, undisclosed high Stage 3 formation rates, overstated credit models, and deteriorating customer credit quality. The lead plaintiff deadline is August 4, 2026.

Rosen Law Firm is encouraging investors who purchased securities of First Solar, Veritone, and Alibaba during specified periods to join class action lawsuits. First Solar faces allegations of overstating its capacity to manage U.S. tariff impacts and understating negative effects on 2026 fiscal year performance. The lead plaintiff deadline for First Solar is August 24, 2026.

Rosen Law Firm is alerting Sportradar Group AG investors who purchased shares between November 7, 2024 and April 21, 2026 about a July 17, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Sportradar made false statements about compliance and ethics while secretly working with black-market gambling operators and maintaining inadequate Know-Your-Customer processes.

Rosen Law Firm has filed a class action lawsuit on behalf of Genius Group Limited (GNS) investors who purchased or sold securities between April 12, 2022 and May 30, 2025. The lawsuit alleges that Citadel Securities LLC and Virtu Americas LLC engaged in illegal 'spoofing' practices—submitting and cancelling orders without intent to execute them—to manipulate stock prices and mislead market participants about supply, demand, and volatility. The deadline to serve as lead plaintiff is August 28, 2026.

Rosen Law Firm is encouraging investors who purchased Badger Meter common stock between April 18, 2024 and April 16, 2026 to join a securities class action lawsuit. The lawsuit alleges that Badger Meter made materially false and misleading statements about its financial results and growth prospects by concealing a practice of pulling forward customer orders to recognize revenue early, which masked weakening demand and deteriorating order trends. The lead plaintiff deadline is August 3, 2026.

THEA, a predictive behavioral AI network focused on risk markets, announced $8 million in financing led by Maven11 Capital. However, the article begins with a retraction notice advising readers to disregard the original news release, creating significant uncertainty about the announcement's validity.

Rosen Law Firm is encouraging investors who purchased securities of Nano-X Imaging Ltd. (NNOX) between March 31, 2025 and April 17, 2026 to join a class action lawsuit. The firm alleges that Nano-X made false statements about operational efficiency and product demand, while concealing poor manufacturing alignment, increased operating expenses, and cash burn. The lead plaintiff deadline is August 11, 2026. The firm is also investigating potential securities claims for ADMA Biologics and DNOW Inc.

Rosen Law Firm is notifying investors in FS KKR Capital Corp. (FSK), ChampionX Corporation (CHX), and Lucid Group, Inc. (LCID) of upcoming lead plaintiff deadlines in securities class action lawsuits. FSK investors have until July 6, 2026, while CHX and LCID have July 14 and unspecified deadlines respectively. The lawsuits allege false statements regarding portfolio valuations, operational effectiveness, and business prospects.

Rosen Law Firm announces securities class action lawsuits against AeroVironment, Futu Holdings Limited, and TruBridge, Inc. AeroVironment is accused of making false statements about competition risks related to U.S. Space Force contracts. Investors with losses exceeding $100,000 are encouraged to join the class actions before the July 27, 2026 lead plaintiff deadline.

Rosen Law Firm is notifying investors about ongoing securities class action lawsuits against Roblox Corporation and FS KKR Capital Corp. The Roblox lawsuit alleges the company made materially false statements about its organic growth potential, concealing that age verification rollout would cause significant growth slowdown. Investors who purchased shares during specified periods are encouraged to join the class action before respective deadlines.

Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.

Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited (RGC) and AeroVironment, Inc. (AVAV) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure during their respective class periods.

Fluency has issued a retraction notice advising that a previous news release from June 11, 2026, regarding CVS using Fluency to close enterprise AI deployment gaps should be disregarded by journalists and readers.

Thor Industries' Board of Directors approved a regular quarterly cash dividend of $0.52 per share, payable on July 15, 2026, to shareholders of record as of July 1, 2026. The company is the world's largest manufacturer of recreational vehicles.

Rosen Law Firm is urging investors who purchased Graphic Packaging Holding Company (GPK) securities between February 4, 2025 and February 2, 2026 to join a class action lawsuit. The lawsuit alleges that the company made false statements regarding inventory management issues, reduced demand, increased costs, and overstated its business model strength. Investors must act by the July 6, 2026 lead plaintiff deadline.

Rosen Law Firm is urging Stellantis N.V. investors who purchased stock between February 26, 2025 and February 5, 2026 to join a securities class action lawsuit before the June 8, 2026 deadline. The lawsuit alleges that Stellantis made false statements about its earnings growth potential and electrification strategy, and was not well-positioned to capitalize on EV opportunities, ultimately requiring significant charges to shift away from battery-powered electric vehicles.